Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.com/index.html

Latest From Daiichi Sankyo Co., Ltd.

Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

China Research & Development

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

The weak yen helped push up both global revenues and costs for major Japanese firms in the fiscal year ended 31 March, while good mainstay growth benefited Daiichi Sankyo and Astellas. Chugai meanwhile had a challenging start to its calendar financial year due to lower pandemic drug stockpiling.

Japan Sales & Earnings

Asian Industry Groups Push For Universal Care, E-Labeling, Flexible Supply Chain

An annual meeting of Asian pharma industry groups in Tokyo recognized the need for faster joint regulatory allowance for second suppliers to stabilize the supply chain, drive e-labeling for patients and expand universal healthcare to better cover expensive therapeutics.

Asia Pacific Regulation

Cash-Rich SynOx Well Placed To Compete In Hot TGCT Field

Ono’s just-announced purchase of Deciphera has put the tenosynovial giant cell tumor space under the spotlight and SynOx is making strides to stay at the head of the pack helped by significant financing.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Ambit Biosciences Corporation
    • Asubio Pharmaceuticals, Inc.
    • Daiichi Sankyo RD Novare Co., Ltd.
    • Kitasato Daiichi Sankyo K.K.
    • Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
    • Plexxikon Inc.
    • Ranbaxy Laboratories Ltd.
    • Roxro Pharma, Inc.
    • Sankyo Pharma
    • Suntory Pharmaceutical
    • U3 Pharma AG
    • Daiichi Sankyo India Pharma Private Limited
    • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
    • Zenotech Laboratories Ltd.
    • Daiichi Sankyo Vietnam Company Limited.
UsernamePublicRestriction

Register